Federal Trade Commission Cracks Down On Unproven COVID-19 Treatment
The Federal Trade Commission issued warning letters to several companies that marketed an unproven drug to treat COVID-19. Sales of the nonapproved drug, thymosin alpha-1, were first reported by NPR.